241 related articles for article (PubMed ID: 17030519)
1. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model.
Baines SD; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2006 Nov; 58(5):1062-5. PubMed ID: 17030519
[TBL] [Abstract][Full Text] [Related]
2. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model.
Freeman J; Baines SD; Saxton K; Wilcox MH
J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547
[TBL] [Abstract][Full Text] [Related]
3. Evidence for low risk of Clostridium difficile infection associated with tigecycline.
Wilcox MH
Clin Microbiol Infect; 2007 Oct; 13(10):949-52. PubMed ID: 17697004
[TBL] [Abstract][Full Text] [Related]
4. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083
[TBL] [Abstract][Full Text] [Related]
5. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model.
Baines SD; Freeman J; Wilcox MH
J Antimicrob Chemother; 2005 Jun; 55(6):974-82. PubMed ID: 15860551
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model.
Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH
J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940
[TBL] [Abstract][Full Text] [Related]
7. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH
J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.
Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH
J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928
[TBL] [Abstract][Full Text] [Related]
9. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model.
Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161
[TBL] [Abstract][Full Text] [Related]
10. Tigecycline for the treatment of severe Clostridium difficile infection.
Larson KC; Belliveau PP; Spooner LM
Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
[TBL] [Abstract][Full Text] [Related]
11. Activity of tigecycline against recent European clinical isolates of Clostridium difficile.
Hawser SP
Int J Antimicrob Agents; 2010 Jan; 35(1):97-8. PubMed ID: 19892528
[No Abstract] [Full Text] [Related]
12. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
Poilane I; Fantinato C; Cruaud P; Collignon A
Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of Clostridium difficile in Scotland.
Wiuff C; Brown DJ; Mather H; Banks AL; Eastaway A; Coia JE
J Infect; 2011 Apr; 62(4):271-9. PubMed ID: 21300104
[TBL] [Abstract][Full Text] [Related]
14. Emergence of reduced susceptibility to metronidazole in Clostridium difficile.
Baines SD; O'Connor R; Freeman J; Fawley WN; Harmanus C; Mastrantonio P; Kuijper EJ; Wilcox MH
J Antimicrob Chemother; 2008 Nov; 62(5):1046-52. PubMed ID: 18693234
[TBL] [Abstract][Full Text] [Related]
15. A case-control study of community-associated Clostridium difficile infection.
Wilcox MH; Mooney L; Bendall R; Settle CD; Fawley WN
J Antimicrob Chemother; 2008 Aug; 62(2):388-96. PubMed ID: 18434341
[TBL] [Abstract][Full Text] [Related]
16. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
[TBL] [Abstract][Full Text] [Related]
17. Mixed infection by Clostridium difficile in an in vitro model of the human gut.
Baines SD; Crowther GS; Todhunter SL; Freeman J; Chilton CH; Fawley WN; Wilcox MH
J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection.
Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH
J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180
[TBL] [Abstract][Full Text] [Related]
19. Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection.
Chilton CH; Crowther GS; Śpiewak K; Brindell M; Singh G; Wilcox MH; Monaghan TM
J Antimicrob Chemother; 2016 Apr; 71(4):975-85. PubMed ID: 26759363
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model.
Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH
J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
